Revolution Medicines, Inc. RVMD Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revolution Medicines, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revolution Medicines, Inc.'s operating lease right-of-use asset amortization?
- Revolution Medicines, Inc. (RVMD) reported operating lease right-of-use asset amortization of $2.19M in Q1 2026.
- How has Revolution Medicines, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Revolution Medicines, Inc.'s operating lease right-of-use asset amortization increased by 24.6% year-over-year, from $1.76M to $2.19M.
- What is the long-term trend for Revolution Medicines, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s operating lease right-of-use asset amortization has grown at a 25.6% compound annual growth rate (CAGR), from $3.18M to $7.91M.